A Randomized Phase III Study to Investigate the Efficacy and Safety of Docetaxel Plus Capecitabine vs. Vinorelbine Plus Capecitabine Followed by Capecitabine Alone as First Line Therapy on Locally Advanced and Metastatic Breast Cancer Patients.

Trial Profile

A Randomized Phase III Study to Investigate the Efficacy and Safety of Docetaxel Plus Capecitabine vs. Vinorelbine Plus Capecitabine Followed by Capecitabine Alone as First Line Therapy on Locally Advanced and Metastatic Breast Cancer Patients.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Capecitabine (Primary) ; Docetaxel (Primary) ; Vinorelbine (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Jun 2014 Results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
    • 24 May 2014 Status changed from recruiting to active, no longer recruiting.
    • 06 Dec 2011 Results presented at the 34th Annual San Antonio Breast Cancer Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top